Samrat Pharmachem Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Samrat Pharmachem Ltd. on BSE

Search Inside the pdf :

Samrat Pharmachem Ltd.

25 Jul 2025

342.95

-0.71%

Company Update

Samrat Pharmachem Ltd-$ - 530125 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Re-appointment of Mr. Lalit Mehta as Chairman & Managing Director, Mr. Rajesh Mehta as Executive Director & Mr. Megh Mehta as Executive Director w.e.f. 01-04-2026

pdf

Samrat Pharmachem Ltd.

18 Jul 2025

342.95

-0.71%

Company Update

Samrat Pharmachem Ltd-$ - 530125 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate u/r 74(5) for the quarter ended June 30, 2025

pdf

Samrat Pharmachem Ltd.

16 Jul 2025

342.95

-0.71%

Company Update

Samrat Pharmachem Ltd-$ - 530125 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Appointment of Mr. Piyush Gangji Dharod as Non-Executive Independent Director of the Company w.e.f. July 16, 2025

pdf

Samrat Pharmachem Ltd.

01 Jul 2025

342.95

-0.71%

Company Update

Samrat Pharmachem Ltd-$ - 530125 - Announcement under Regulation 30 (LODR)-Resignation of Director

BSE India

Resignation of Ms. Renu Dharod (DIN: 07063088) as Non-Executive Independent Director of the company w.e.f. close of business hours on June 30, 2025

pdf

Samrat Pharmachem Ltd.

26 Jun 2025

342.95

-0.71%

Corp. Note

Samrat Pharmachem Ltd-$ - 530125 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySamrat Pharmachem Ltd- 2CIN NO.L24230GJ1992PLC017820 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY BBB- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Nishant Kankaria Designation: Company Secretary and Compliance Officer EmailId: contact@samratpharmachem.in Name of the Chief Financial Officer: Rajesh Mehta Designation: CFO EmailId: contact@samratpharmachem.in Date: 26/06/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Samrat Pharmachem Ltd.

23 Jun 2025

342.95

-0.71%

Board Meeting

Samrat Pharmachem Ltd-$ - 530125 - Board Meeting Intimation for Un-Audited Financial Results For The Quarter …

BSE India

Samrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 ,inter alia, to consider and approve the un-audited financial results for the quarter ended 30-06-2025

pdf